Imigran

Sumatriptan, the active ingredient in Imigran, is a triptan presented as a nasal spray for nasal use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients who require rapid symptom relief.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable, traceable sourcing for acute migraine therapy. The company manages export logistics and regulatory documentation to ensure timely delivery to authorized healthcare providers.

Imigran (sumatriptan) is a selective 5‑HT1B/1D receptor agonist used in the migraine disease pathway.

- Migraine attack: aborts headache and associated symptoms such as nausea, photophobia, and phonophobia. - Migraine with aura: provides rapid relief of pain and aura manifestations. - Acute migraine: reduces the need for additional rescue medication and improves functional recovery.

Common side effects are generally mild and transient.

Common Side Effects: - Taste disturbance: altered or unpleasant taste in the mouth. - Nasal irritation: burning or stinging sensation in the nasal passages. - Dizziness: feeling light‑headed or unsteady. - Fatigue: unusual tiredness after dosing. - Nausea: mild stomach upset. - Paresthesia: tingling sensations in the face or extremities.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate cardiac ischemia. - Severe hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperreflexia, fever when combined with serotonergic agents. - Allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm. - Ischemic events: stroke or myocardial infarction.

Before using Imigran, consider the following safety measures. - Cardiovascular disease: avoid if you have coronary artery disease, uncontrolled hypertension, or history of stroke. - Hemiplegic or basilar migraine: contraindicated due to risk of vascular complications. - Concomitant MAO inhibitors: discontinue MAO‑I therapy at least 14 days before use. - Pregnancy and lactation: discuss risks with a healthcare professional; safety data are limited. - Drug interactions: review all current medications with a prescriber to prevent adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Sumatriptan may interact with several drug classes; monitor accordingly.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergot alkaloids (e.g., ergotamine): additive vasoconstriction can cause coronary spasm. - Other triptans: cumulative vasoconstrictive effect increases cardiovascular risk. - SSRIs/SNRIs: heightened potential for serotonin syndrome. - Monoamine oxidase inhibitors: similar to MAO‑I risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure‑lowering effects. - Oral contraceptives: possible increase in migraine frequency. - CYP2D6 inhibitors (e.g., fluoxetine): may raise sumatriptan plasma levels. - Antihistamines: can increase sedation or dizziness. - Alcohol: may exacerbate dizziness and hypotension.